Baxter International (NYSE:BAX) Updates FY 2025 Earnings Guidance

Key Points

• Baxter International has updated its FY 2025 earnings guidance, projecting earnings per share (EPS) of 2.420-2.520 and revenues of $11.3 billion to $11.4 billion, closely in line with consensus estimates.
• The company's stock has experienced an 18.0% decline recently, with analysts providing mixed ratings and target price adjustments.
• Baxter International announced a quarterly dividend payout of $0.17, leading to an annualized yield of 2.96%, with the ex-dividend date set for August 29th.

Baxter International (NYSE:BAX - Get Free Report) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share guidance of 2.420-2.520 for the period, compared to the consensus earnings per share estimate of 2.517. The company issued revenue guidance of $11.3 billion-$11.4 billion, compared to the consensus revenue estimate of $11.4 billion. Baxter International also updated its Q3 2025 guidance to 0.580-0.620 EPS.

Baxter International Stock Performance

NYSE BAX traded up $0.45 during trading hours on Monday, hitting $22.41. 11,386,479 shares of the stock were exchanged, compared to its average volume of 5,060,967. The company has a market cap of $11.50 billion, a price-to-earnings ratio of -74.70, a price-to-earnings-growth ratio of 0.71 and a beta of 0.59. Baxter International has a 12-month low of $21.33 and a 12-month high of $40.49. The stock has a 50-day moving average of $29.52 and a 200 day moving average of $31.03. The company has a quick ratio of 1.40, a current ratio of 2.02 and a debt-to-equity ratio of 1.33.

Baxter International (NYSE:BAX - Get Free Report) last announced its earnings results on Thursday, July 31st. The medical instruments supplier reported $0.59 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.60 by ($0.01). The business had revenue of $2.81 billion for the quarter, compared to analyst estimates of $2.82 billion. Baxter International had a positive return on equity of 16.93% and a negative net margin of 1.42%. The business's revenue was up 4.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.68 EPS. As a group, equities research analysts forecast that Baxter International will post 2.48 earnings per share for the current year.

Baxter International Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 1st. Investors of record on Friday, August 29th will be issued a $0.17 dividend. The ex-dividend date of this dividend is Friday, August 29th. This represents a $0.68 annualized dividend and a yield of 3.0%. Baxter International's dividend payout ratio is currently -226.67%.

Analyst Ratings Changes

A number of analysts have weighed in on BAX shares. Citigroup dropped their target price on shares of Baxter International from $34.00 to $32.00 and set a "neutral" rating on the stock in a report on Wednesday, July 9th. The Goldman Sachs Group lowered shares of Baxter International from a "buy" rating to a "neutral" rating and set a $25.00 price objective for the company. in a research note on Friday. Wells Fargo & Company reduced their price target on shares of Baxter International from $33.00 to $24.00 and set an "equal weight" rating for the company in a research report on Friday. Morgan Stanley cut their price objective on shares of Baxter International from $28.00 to $27.00 and set an "underweight" rating on the stock in a research report on Tuesday, July 15th. Finally, Stifel Nicolaus reiterated a "hold" rating and set a $25.00 price target (down previously from $36.00) on shares of Baxter International in a report on Monday. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Baxter International currently has an average rating of "Hold" and a consensus price target of $30.67.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.